LIVIVO - Search results -

Search results

Result 1 - 10 of total 61

Search options

Article ; Online: Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice.

Mullane, Kathleen M / Dubberke, Erik R

2019 Volume 33, Issue 9, Page(s) e13564

Abstract: These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice address the prevention and management of Clostridium difficile infection in solid organ transplant (SOT) recipients. Clostridioides (formerly ... ...

Abstract	These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice address the prevention and management of Clostridium difficile infection in solid organ transplant (SOT) recipients. Clostridioides (formerly Clostridium) difficile infection (CDI) is among the most common hospital acquired infections. In SOT recipients, the incidence of CDI varies by type and number or organs transplanted. While a meta-analysis of published literature found the prevalence of postoperative CDI in the general surgical population to be approximately 0.51%, the prevalence of CDI that is seen in the solid organ transplant population ranges from a low of 3.2% in the pancreatic transplant population to 12.7% in those receiving multiple organ transplants. There are no randomized, controlled trials evaluating the management of CDI in the SOT population. Herein is a review and summary of the currently available literature that has been synthesized into updated treatment guidelines for the management of CDI in the SOT population.
MeSH term(s)	Anti-Bacterial Agents/therapeutic use ; Clostridium Infections/diagnosis ; Clostridium Infections/drug therapy ; Clostridium Infections/etiology ; Clostridium difficile/isolation & purification ; Disease Management ; Humans ; Organ Transplantation/adverse effects ; Practice Guidelines as Topic/standards ; Societies, Medical ; Transplant Recipients
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2019-06-20
Publishing country	Denmark
Document type	Journal Article
ZDB-ID	639001-8
ISSN	1399-0012 ; 0902-0063
ISSN (online)	1399-0012
ISSN	0902-0063
DOI	10.1111/ctr.13564
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Carnobacterium

Miller, Kathleen M / Tang, Flora / Li, Sixuan / Mullane, Kelli K / Shelton, Brontë R / Bui, Lam / Bartlett, Douglas H / Nicholson, Wayne L

Astrobiology

2022 Volume 23, Issue 1, Page(s) 94–104

Abstract: Several permanently cold solar system bodies are being investigated with regard to their potential habitability, including Mars and icy moons. In such locations, microbial life would have to cope with low temperatures and both high and low pressures, ... ...

Abstract	Several permanently cold solar system bodies are being investigated with regard to their potential habitability, including Mars and icy moons. In such locations, microbial life would have to cope with low temperatures and both high and low pressures, ranging from ∼10
MeSH term(s)	Extraterrestrial Environment ; Carnobacterium ; Solar System ; Oceans and Seas ; Moon ; Mars ; Exobiology
Language	English
Publishing date	2022-11-24
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2047736-3
ISSN	1557-8070 ; 1531-1074
ISSN (online)	1557-8070
ISSN	1531-1074
DOI	10.1089/ast.2022.0043
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: American Society for Transplantation and Cellular Therapy Series: #5-Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients.

Alonso, Carolyn D / Maron, Gabriela / Kamboj, Mini / Carpenter, Paul A / Gurunathan, Arun / Mullane, Kathleen M / Dubberke, Erik R

Transplantation and cellular therapy

2022 Volume 28, Issue 5, Page(s) 225–232

Abstract: The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious disease guidelines for hematopoietic ...

Abstract	The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and then answered FAQs and finalized topics with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. This fifth guideline in the series focuses on Clostridioides difficile infection with FAQs that address the prevalence, incidence, clinical features, colonization versus infection, clinical complications, diagnostic considerations, pharmacological therapies for episodic or recurrent infection, and the roles of prophylactic antibiotics, probiotics, and fecal microbiota transplantation.
MeSH term(s)	Adult ; Cell- and Tissue-Based Therapy ; Child ; Clostridium Infections/therapy ; Fecal Microbiota Transplantation ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Transplant Recipients ; United States/epidemiology
Language	English
Publishing date	2022-02-22
Publishing country	United States
Document type	Practice Guideline ; Journal Article
ZDB-ID	3062231-1
ISSN	2666-6367
ISSN (online)	2666-6367
DOI	10.1016/j.jtct.2022.02.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?

Pettit, Natasha N / Pisano, Jennifer / Nguyen, Cynthia T / Lew, Alison K / Hazra, Aniruddha / Sherer, Renslow / Mullane, Kathleen M

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2020 Volume 73, Issue 11, Page(s) e3990–e3995

Abstract: Background: Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance <30mL/min or requiring renal replacement therapy). Few studies have evaluated RDV in ... ...

Abstract	Background: Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance <30mL/min or requiring renal replacement therapy). Few studies have evaluated RDV in patients with SRI. Methods: Hospitalized patients who received RDV between 1 May 2020 and 31 October 2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) in patients with and without SRI, including hepatotoxicity, nephrotoxicity, any reported AE, mortality, and length of stay. Results: Of a total of 135 patients, 20 had SRI. Patients with SRI were significantly older (70 vs 54 years, P = .0001). The incidence of possible AEs was 30% among those with SRI vs 11% without (P = .06). Liver function test (LFT) elevations occurred in 10% vs 4% (P = .28), and serum creatinine (SCr) elevations in 27% vs 6% (P = .02) of patients with SRI vs without, respectively. LFT and SCr elevations were not attributed to RDV in either group. Mortality and length of stay were consistent with historical controls. Conclusions: RDV AEs occurred infrequently and overall were not significantly different between those with and without SRI. While more of patients with SRI experienced SCr elevations, 3 (75%) patients had acute kidney injury prior to RDV. The use of RDV in this small series of patients with SRI appeared to be relatively safe, and the potential benefit outweighed the theoretical risk of liver or renal toxicity. Additional studies are needed to confirm this finding.
MeSH term(s)	Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; Humans ; Retrospective Studies ; SARS-CoV-2
Chemical Substances	Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
Language	English
Publishing date	2020-12-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciaa1851
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Fidaxomicin: first-in-class macrocyclic antibiotic.

Mullane, Kathleen M / Gorbach, Sherwood

Expert review of anti-infective therapy

2011 Volume 9, Issue 7, Page(s) 767–777

Abstract: The incidence of Clostridium difficile has doubled over the past 15 years, and rising mortality rates associated with this infection have followed in its wake. C. difficile infection (CDI) has supplanted methicillin-resistant Staphylococcus aureus as the ...

Abstract	The incidence of Clostridium difficile has doubled over the past 15 years, and rising mortality rates associated with this infection have followed in its wake. C. difficile infection (CDI) has supplanted methicillin-resistant Staphylococcus aureus as the major cause of nosocomial infection. An insufficient response rate to currently available CDI therapies has prompted the search for new and alternative treatment modalities for this disease. The investigational pipeline includes evaluation of new antimicrobial agents that exhibit good activity against C. difficile without altering normal gut flora, C. difficile toxin-absorbing compounds, and preformed antibodies and vaccines against C. difficile toxin. In two robust clinical trials comparing fidaxomicin to vancomycin in the treatment of CDI, treatment with fidaxomicin demonstrated a superior global cure (cure without recurrence) rate compared with the current gold standard, vancomycin. Fidaxomicin, the first of a new class of macrocyclic antimicrobial agents, represents an advance in the management of CDI.
MeSH term(s)	Actinomycetales/chemistry ; Actinomycetales/metabolism ; Aminoglycosides/chemistry ; Aminoglycosides/pharmacokinetics ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacokinetics ; Bacterial Proteins/antagonists & inhibitors ; Bacterial Proteins/metabolism ; Clinical Trials, Phase III as Topic ; Clostridium Infections/drug therapy ; Clostridium Infections/microbiology ; Clostridium Infections/pathology ; Clostridium difficile/drug effects ; Clostridium difficile/growth & development ; Cross Infection/drug therapy ; Cross Infection/microbiology ; Cross Infection/pathology ; DNA-Directed RNA Polymerases/antagonists & inhibitors ; DNA-Directed RNA Polymerases/metabolism ; Gastrointestinal Tract/microbiology ; Gastrointestinal Tract/pathology ; Humans ; Microbial Sensitivity Tests ; Nucleic Acid Synthesis Inhibitors/chemistry ; Nucleic Acid Synthesis Inhibitors/pharmacokinetics ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Vancomycin/pharmacokinetics
Chemical Substances	Aminoglycosides ; Anti-Bacterial Agents ; Bacterial Proteins ; Nucleic Acid Synthesis Inhibitors ; Vancomycin (6Q205EH1VU) ; DNA-Directed RNA Polymerases (EC 2.7.7.6) ; lipiarmycin (Z5N076G8YQ)
Language	English
Publishing date	2011-07
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2181279-2
ISSN	1744-8336 ; 1478-7210
ISSN (online)	1744-8336
ISSN	1478-7210
DOI	10.1586/eri.11.53
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.

Pajon, Rolando / Paila, Yamuna D / Girard, Bethany / Dixon, Groves / Kacena, Katherine / Baden, Lindsey R / El Sahly, Hana M / Essink, Brandon / Mullane, Kathleen M / Frank, Ian / Denhan, Douglas / Kerwin, Edward / Zhao, Xiaoping / Ding, Baoyu / Deng, Weiping / Tomassini, Joanne E / Zhou, Honghong / Leav, Brett / Schödel, Florian

Nature medicine

2022 Volume 28, Issue 4, Page(s) 823–830

Abstract: The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2% efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the blinded portion of the Phase 3 Coronavirus Efficacy (COVE) ...

Abstract	The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2% efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the blinded portion of the Phase 3 Coronavirus Efficacy (COVE) trial. While mRNA-1273 demonstrated high efficacy in prevention of COVID-19, including severe disease, its effect on the viral dynamics of SARS-CoV-2 infections is not understood. Here, in exploratory analyses, we assessed the impact of mRNA-1273 vaccination in the ongoing COVE trial (number NCT04470427) on SARS-CoV-2 copy number and shedding, burden of disease and infection, and viral variants. Viral variants were sequenced in all COVID-19 and adjudicated COVID-19 cases (n = 832), from July 2020 in the blinded part A of the study to May 2021 of the open-label part B of the study, in which participants in the placebo arm started to receive the mRNA-1273 vaccine after US Food and Drug Administration emergency use authorization of mRNA-1273 in December 2020. mRNA-1273 vaccination significantly reduced SARS-CoV-2 viral copy number (95% confidence interval) by 100-fold on the day of diagnosis compared with placebo (4.1 (3.4-4.8) versus 6.2 (6.0-6.4) log
MeSH term(s)	2019-nCoV Vaccine mRNA-1273 ; COVID-19/epidemiology ; COVID-19/prevention & control ; Humans ; SARS-CoV-2/genetics ; United States
Chemical Substances	2019-nCoV Vaccine mRNA-1273 (EPK39PL4R4)
Language	English
Publishing date	2022-02-10
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-022-01679-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2023 Volume 77, Issue 8, Page(s) 1102–1110

Abstract: Background: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity ... ...

Abstract	Background: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), a 15-valent pneumococcal conjugate vaccine (PCV), when given to allo-HCT recipients. Methods: Participants received 3 doses of V114 or PCV13 (Prevnar 13; Wyeth LLC) in 1-month intervals starting 3-6 months after allo-HCT. Twelve months after HCT, participants received either PNEUMOVAX 23 or a fourth dose of PCV (if they experienced chronic graft vs host disease). Safety was evaluated as the proportion of participants with adverse events (AEs). Immunogenicity was evaluated by measuring serotype-specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) for all V114 serotypes in each vaccination group. Results: A total of 274 participants were enrolled and vaccinated in the study. The proportions of participants with AEs and serious AEs were generally comparable between intervention groups, and the majority of AEs in both groups were of short duration and mild-to-moderate intensity. For both IgG GMCs and OPA GMTs, V114 was generally comparable to PCV13 for the 13 shared serotypes, and higher for serotypes 22F and 33F at day 90. Conclusions: V114 was well tolerated in allo-HCT recipients, with a generally comparable safety profile to PCV13. V114 induced comparable immune responses to PCV13 for the 13 shared serotypes, and was higher for V114 serotypes 22F and 33F. Study results support the use of V114 in allo-HCT recipients. Clinical Trials Registration. clinicaltrials.gov (NCT03565900) and European Union at EudraCT 2018-000066-11.
MeSH term(s)	Humans ; Vaccines, Conjugate ; Transplant Recipients ; Hematopoietic Stem Cell Transplantation/adverse effects ; Antibodies, Bacterial ; Pneumococcal Infections/drug therapy ; Pneumococcal Vaccines ; Double-Blind Method ; Immunoglobulin G ; Immunogenicity, Vaccine
Chemical Substances	Vaccines, Conjugate ; Antibodies, Bacterial ; Pneumococcal Vaccines ; Immunoglobulin G
Language	English
Publishing date	2023-06-20
Publishing country	United States
Document type	Randomized Controlled Trial ; Clinical Trial, Phase III ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/ciad349
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Herpes zoster and radiation therapy: what radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster.

Macomber, Meghan W / Mullane, Kathleen M / Liauw, Stanley L

Practical radiation oncology

2014 Volume 4, Issue 1, Page(s) 58–64

Abstract: Herpes zoster, a viral disease that is characterized by a painful and blistering eruption in the skin, represents reactivation of latent varicella zoster (chickenpox) virus infection. In high-risk groups such as elderly or immunocompromised patients, the ...

Abstract	Herpes zoster, a viral disease that is characterized by a painful and blistering eruption in the skin, represents reactivation of latent varicella zoster (chickenpox) virus infection. In high-risk groups such as elderly or immunocompromised patients, the incidence of zoster can be as high as 50%. Radiation oncologists are likely to see zoster because cancer, and cancer therapy, can adversely affect immune function. A few reports suggest that radiation therapy is a risk factor for zoster, and that the skin eruption is often in or near the radiation treatment field. The diagnosis is typically made through clinical history and exam, but several tests are available to confirm the diagnosis and differentiate it from other infections or dermatitis. Effective management consists of prompt antiviral medication, acute pain control, appropriate precautions to limit transmission, and referral to specialists in certain cases. Despite appropriate therapy, up to 18% of patients can develop persistent postherpetic neuralgia, defined as pain more than 4 months after resolution of the rash. Several classes of pain medication are available to treat acute or long-term pain. Vaccination against zoster is recommended for patients aged 60 years or older, as it can reduce the incidence and severity of zoster.
MeSH term(s)	Antiviral Agents/therapeutic use ; Herpes Zoster/diagnosis ; Herpes Zoster/prevention & control ; Herpes Zoster/radiotherapy ; Herpes Zoster/therapy ; Humans ; Male ; Middle Aged
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2014-01
Publishing country	United States
Document type	Case Reports ; Journal Article ; Review
ISSN	1879-8519
ISSN (online)	1879-8519
DOI	10.1016/j.prro.2013.02.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.

Chaparro-Rojas, Fredy / Mullane, Kathleen M

Infection and drug resistance

2013 Volume 6, Page(s) 41–53

Abstract: The epidemiology of Clostridium difficile infections (CDI) has evolved during the last decades, with an increase in the reported incidence, severity of cases, and rate of mortality and relapses. These increases have primarily affected some special ... ...

Abstract	The epidemiology of Clostridium difficile infections (CDI) has evolved during the last decades, with an increase in the reported incidence, severity of cases, and rate of mortality and relapses. These increases have primarily affected some special populations including the elderly, patients requiring concomitant antibiotic therapy, patients with renal failure, and patients with cancer. Until recently, the treatment of CDI was limited to either metronidazole or vancomycin. New therapeutic options have emerged to address the shortcomings of current antibiotic therapy. Fidaxomicin stands out as the first-in-class oral macrocyclic antibiotic with targeted activity against C. difficile and minimal collateral damage on the normal colonic flora. Fidaxomicin has demonstrated performance not inferior to what is considered the "gold standard" available therapy for CDI, vancomycin, in two separate Phase III clinical trials, but with significant advantages, including fewer recurrences and higher rates of sustained clinical cures. Fidaxomicin constitutes an important development in targeted antibiotic therapy for CDI and must be considered as a first-line agent for patients with risk factors known to portend relapse and severe infection.
Language	English
Publishing date	2013-06-28
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2494856-1
ISSN	1178-6973
ISSN	1178-6973
DOI	10.2147/IDR.S24434
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients.

Linder, Kathleen A / Kovacs, Christopher / Mullane, Kate M / Wolfe, Cameron / Clark, Nina M / La Hoz, Ricardo M / Smith, Jeannina / Kotton, Camille N / Limaye, Ajit P / Malinis, Maricar / Hakki, Morgan / Mishkin, Aaron / Gonzalez, Arnoldo Adrian / Prono, Maria Dioverti / Ostrander, Darin / Avery, Robin / Kaul, Daniel R

Transplant infectious disease : an official journal of the Transplantation Society

2021 Volume 23, Issue 4, Page(s) e13687

Abstract: Background: Few options are available for cytomegalovirus (CMV) treatment in transplant recipients resistant, refractory, or intolerant to approved agents. Letermovir (LET) is approved for prophylaxis in hematopoietic cell transplant (HCT) recipients, ... ...

Abstract	Background: Few options are available for cytomegalovirus (CMV) treatment in transplant recipients resistant, refractory, or intolerant to approved agents. Letermovir (LET) is approved for prophylaxis in hematopoietic cell transplant (HCT) recipients, but little is known about efficacy in CMV infection. We conducted an observational study to determine the patterns of use and outcome of LET treatment of CMV infection in transplant recipients. Methods: Patients who received LET for treatment of CMV infection were identified at 13 transplant centers. Demographic and outcome data were collected. Results: Twenty-seven solid organ and 21 HCT recipients (one dual) from 13 medical centers were included. Forty-five of 47 (94%) were treated with other agents prior to LET, and 57% had a history of prior CMV disease. Seventy-seven percent were intolerant to other antivirals; 32% were started on LET because of resistance concerns. Among 37 patients with viral load < 1000 international units (IU)/ml at LET initiation, two experienced >1 log rise in viral load by week 12, and no deaths were attributed to CMV. Ten patients had viral load > 1000 IU/ml at LET initiation, and six of 10 (60%) had a CMV viral load < 1000 IU/ml at completion of therapy or last known value. LET was discontinued in two patients for an adverse event. Conclusions: Patients treated with LET with viral load < 1000 IU/ml had good virologic outcomes. Outcomes were mixed when LET was initiated at higher viral loads. Further studies on combination therapy or alternative LET dosing are needed.
MeSH term(s)	Acetates/therapeutic use ; Antiviral Agents/therapeutic use ; Cytomegalovirus Infections/drug therapy ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Quinazolines ; Transplant Recipients ; Viral Load
Chemical Substances	Acetates ; Antiviral Agents ; Quinazolines ; letermovir (1H09Y5WO1F)
Language	English
Publishing date	2021-07-20
Publishing country	Denmark
Document type	Journal Article ; Observational Study
ZDB-ID	1476094-0
ISSN	1399-3062 ; 1398-2273
ISSN (online)	1399-3062
ISSN	1398-2273
DOI	10.1111/tid.13687
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5100: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito